---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-023937"
form_type: "8-K"
ticker: "NTRB"
cik: "0001676047"
company_name: "NutriBand Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:38:38.382302+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nutriband secures $2M credit line for AVERSA Fentanyl commercialization

## Summary
- Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.
- Proceeds to fund FDA approval process and commercial manufacturing of AVERSA Fentanyl.
- AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system using proprietary technology.
- Potential peak annual US sales estimated at $80M-$200M per 2022 market analysis.
- Financing is non-dilutive, supporting growth strategy without equity dilution.

## SEC filing metadata
- accession: 0001213900-23-023937
- form_type: 8-K
- ticker: NTRB
- cik: 0001676047
- company_name: NutriBand Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676047/000121390023023937/0001213900-23-023937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676047/000121390023023937/ea175942-8k_nutriband.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-023937
- JSON: https://secwatch.observer/filing/0001213900-23-023937.json
- Plain text: https://secwatch.observer/filing/0001213900-23-023937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.